Response to the Letter to the Editor Entitled “Critical Reappraisal of Obinutuzumab Randomized Trials in Membranous Nephropathy”

Kajaree Giri, Richard J Glassock, Fernando C Fervenza · 2026

Read Response to the Letter to the Editor Entitled “Critical Reappraisal of Obinutuzumab Randomized Trials in Membranous Nephropathy” by Kajaree Giri, Richard J Glassock, Fernando C Fervenza (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13427534.txt.

Description

Giri, Glassock, and Fervenza reply to critics of obinutuzumab trials in primary membranous nephropathy, a kidney disease. They concede the MAJESTY trial ideally would have tested obinutuzumab against rituximab, the current standard. But a trial to prove it better would need 1,005 to 3,684 randomized patients. The range hinged on the remission rates assumed, making such a trial too big to run. Beating tacrolimus could still win United States approval. It could also help patients who cannot get rituximab paid for.

Catalog record

CREATORKajaree Giri, Richard J Glassock, Fernando C Fervenza
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE3 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13427534

Browse the full library · About the Tower of Babel